The misuse and overdose of antimicrobial medicines are fostering the emergence of novel drug-resistant pathogens, providing negative repercussions not only on the global healthcare system due to the rise of long-term or chronic patients and inefficient therapies but also on the world trade, productivity, and, in short, to the global economic growth. In view of these scenarios, novel action plans to constrain this antibacterial resistance are needed. Thus, given the proven antiproliferative tumoral and microbial features of thiosemicarbazone (TSCN) ligands, we have here synthesized a novel effective antibacterial copper–thiosemicarbazone complex, demonstrating both its solubility profile and complex stability under physiological conditions, along with their safety and antibacterial activity in contact with human cellular nature and two most predominant bacterial strains, respectively. A significant growth inhibition (17% after 20 h) is evidenced over time, paving the way toward an effective antibacterial therapy based on these copper–TSCN complexes.

中文翻译：

---

证明新型铜-缩氨基硫脲复合物的抗菌治疗活性

抗菌药物的滥用和过量正在促进新型耐药病原体的出现，不仅因长期或慢性患者的增加和治疗效率低下而对全球医疗保健系统产生负面影响，而且对世界贸易、生产力产生负面影响。 ，简而言之，对全球经济增长。鉴于这些情况，需要制定新的行动计划来限制这种抗菌药物耐药性。因此，考虑到缩氨基硫脲（TSCN）配体已被证明的抗增殖肿瘤和微生物特性，我们在这里合成了一种新型有效的抗菌铜-缩氨基硫脲复合物，证明了其在生理条件下的溶解度和复合物稳定性，以及它们在环境中的安全性和抗菌活性。分别与人类细胞性质和两种最主要的细菌菌株接触。随着时间的推移，明显的生长抑制（20小时后17%）被证明，为基于这些铜-TSCN复合物的有效抗菌治疗铺平了道路。